Mobilization of dendritic cells in cancer patients treated with granulocyte colony‐stimulating factor and chemotherapy

Díaz-Montero

The Journal of Immunology

et al. 2009

100

Recent preclinical studies suggest that vaccination following adoptive transfer of CD8+ T cells into a lymphopenic host can augment the therapeutic antitumor responses of the transferred cells. However, the mechanism by which the lymphopenic microenvironment benefits Ag-specific CD8+ T cell responses remains elusive. We show herein that induction of lymphodepletion by a single 4 mg cyclophosphamide (CTX) treatment induces a marked expansion of immature dendritic cells (DCs) in the peripheral blood on days 8–16 post-CTX (termed restoration phase). In vitro, these DCs were functional, because they showed normal phagocytosis and effective Ag presentation capability upon activation. In vivo, administration of the TLR3 agonist poly(I:C) at the peak of DC expansion (day 12 postlymphopenia) induced inflammatory cytokine production and increases in the number of activated DCs in lymph nodes. Importantly, boosting with gp10025–33 melanoma peptide combined with poly(I:C) 12 days after an initial priming with the same regimen significantly increased the expansion and the antitumor efficacy of adoptively transferred pmel-1 CD8+ T cells. These responses were abrogated after depletion of activated DCs during Ag boosting. In conclusion, our data show that CTX treatment induces, during the restoration phase, expansion of immature DCs, which are functional and can be exploited in vivo to foster more effective antitumor adoptive immunotherapy strategies.

show abstract

Section: Discussionsupporting

confidence: 93%

Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)

Díaz-Montero

The Journal of Immunology

et al. 2009

100

show abstract

“…3). In line with our results, previous studies also showed increases in the numbers of DCs during the restoration phase in the peripheral blood of cancer patients receiving combinatorial treatment with CTX and G-CSF (38–40). Although it was not clear in these studies whether the increase in the frequency of DCs was solely due to the effects induced by CTX or the growth factors, our results demonstrate that CTX per se is capable of inducing DC expansion in the peripheral blood in a murine model.…”

Section: Discussionsupporting

confidence: 93%

Cyclophosphamide Induces Dynamic Alterations in the Host Microenvironments Resulting in a Flt3 Ligand-Dependent Expansion of Dendritic Cells

The Journal of Immunology

El‐Naggar

et al. 2010

Preconditioning a recipient host with lymphodepletion can markedly augment adoptive T cell therapy. However, the precise mechanisms involved are poorly understood. In a recent study, we observed a significant increase in the circulating levels of dendritic cells (DCs; CD11c+CD11b+) during the recovery from cyclophosphamide (CTX)-induced lymphodepletion. Herein, we demonstrate that the CTX-induced DC expansion was not altered by adjuvant chemotherapy or tumor burden but was augmented by coadministration of granulocyte-colony stimulating factor. Although the increase in the number of DCs was preceded by a systemic expansion of a population expressing the phenotype of myeloid-derived suppressor cells (Gr-1+CD11b+), depletion of these Gr-1+ cells had no effect on the noted expansion. Moreover, when Gr-1highCD11bhigh cells were sorted from CTX-treated mice and adoptively transferred into control or CTX-treated recipients, they did not differentiate into DCs. Post-CTX expansion of DCs was associated with proliferation of DCs in bone marrow (BM) during the lymphopenic phase and in the blood and spleen during the recovery phase. Furthermore, adoptive transfer of BM cells from CTX-treated mice produced equal numbers of DCs in the blood of either CTX-treated or untreated recipients. CTX induced a dynamic surge in the expression of growth factors and chemokines in BM, where CCR2 and Flt3 signaling pathways were critical for DC expansion. In sum, our data suggest that CTX induces proliferation of DCs in BM prior to their expansion in the periphery. Targeting DCs at these phases would significantly improve their contribution to the clinical application of lymphodepletion to adoptive immunotherapy

show abstract

“…Indeed, we tested this hypothesis recently using poly(I:C), the typical TLR3 agonist, to mature DCs and induce their migration to lymph nodes to enhance antigen-specific T cell responses (25). Our observation of post CTX DC expansion is consistent with the recent clinical studies that showed increases in the number of DCs in PBL of cancer patients treated with CTX and G-CSF (26, 27). Although these reports did not examine the sole effect of CTX or G-CSF on DC mobilization, the current results showed that CTX per se was capable of inducing systemic DC expansion.…”

Section: Discussionsupporting

confidence: 92%

Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide

El-Nagaar

et al. 2012

Cellular Immunology